183 related articles for article (PubMed ID: 21042412)
21. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
[TBL] [Abstract][Full Text] [Related]
22. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
23. Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.
Fidyt K; Pastorczak A; Cyran J; Crump NT; Goral A; Madzio J; Muchowicz A; Poprzeczko M; Domka K; Komorowski L; Winiarska M; Harman JR; Siudakowska K; Graczyk-Jarzynka A; Patkowska E; Lech-Maranda E; Mlynarski W; Golab J; Milne TA; Firczuk M
Oncogene; 2022 Mar; 41(11):1600-1609. PubMed ID: 35091682
[TBL] [Abstract][Full Text] [Related]
24. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
25. Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.
Schroeder MP; Bastian L; Eckert C; Gökbuget N; James AR; Tanchez JO; Schlee C; Isaakidis K; Häupl B; Baum K; Migueles Lozano OA; Kouidri K; Pan KT; Urlaub H; Schwartz S; Burmeister T; von Stackelberg A; Hoelzer D; Pfeiffer H; Rieger MA; Göllner S; Oellerich T; Horstman M; Schrappe M; Wolf J; Kirschner-Schwabe R; Brüggemann M; Müller-Tidow C; Serve H; Neumann M; Baldus CD
Sci Rep; 2019 Mar; 9(1):4188. PubMed ID: 30862934
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
[TBL] [Abstract][Full Text] [Related]
27. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
28. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
30. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
31. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
32. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A; Valsecchi L; Quadri M; Watrin T; Scharov K; Procopio S; Tu JW; Vogt M; Savino AM; Silvestri D; Valsecchi MG; Biondi A; Borkhardt A; Bhatia S; Cazzaniga G; Fazio G; Bardini M; Palmi C
Biochem Pharmacol; 2023 Nov; 217():115809. PubMed ID: 37717691
[TBL] [Abstract][Full Text] [Related]
33. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
35. Analysis of clonal rearrangements of the Ig heavy chain locus in acute leukemia.
Height SE; Swansbury GJ; Matutes E; Treleaven JG; Catovsky D; Dyer MJ
Blood; 1996 Jun; 87(12):5242-50. PubMed ID: 8652839
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model.
Canale S; Cocco C; Frasson C; Seganfreddo E; Di Carlo E; Ognio E; Sorrentino C; Ribatti D; Zorzoli A; Basso G; Dufour C; Airoldi I
Leukemia; 2011 Dec; 25(12):1815-24. PubMed ID: 21701492
[TBL] [Abstract][Full Text] [Related]
37. Nationwide study of pediatric B-cell precursor acute lymphoblastic leukemia with chromosome 8q24/MYC rearrangement in Japan.
Sakaguchi K; Imamura T; Ishimaru S; Imai C; Shimonodan H; Fujita N; Okada K; Taketani T; Kanai R; Tauchi H; Kato M; Kojima Y; Watanabe A; Deguchi T; Hashii Y; Kiyokawa N; Taki T; Saito AM; Horibe K; Manabe A; Sato A; Koh K
Pediatr Blood Cancer; 2020 Jul; 67(7):e28341. PubMed ID: 32323914
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
39. Support of BCP-ALL-cells by autologous bone marrow Th-cells involves induction of AID expression but not widespread AID off-target mutagenesis.
Traxel S; Lehmann J; Richard S; Sidorov S; Niggli F; Berger C; Nadal D; Bürgler S
Cancer Immunol Immunother; 2021 Aug; 70(8):2275-2289. PubMed ID: 33507341
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
